Immunicum AB (DE:1YG0)

FRANKFURT:1YG0

1YG0

Immunicum AB

RESEARCH TOOLSreports

Want to see DE:1YG0 full AI Analyst Report?

Immunicum AB (1YG0) Price & Analysis

1 Followers

1YG0 Stock Chart & Stats

€0.49

-€0.01(-1.68%)

At close: Jan 08 4:00 PM EST

€0.49

-€0.01(-1.68%)

Day’s Range― - ―

52-Week Range€0.35 - €0.87

Previous CloseN/A

Volume0.00

Average Volume (3M)16.00

Market Cap

€32.47M

Enterprise Value€236.89M

Total Cash (Recent Filing)€74.13M

Total Debt (Recent Filing)€18.67M

Price to Earnings (P/E)―

Beta0.13

Next Earnings

Aug 20, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.90

Shares Outstanding62,584,580

10 Day Avg. Volume50

30 Day Avg. Volume16

Financial Highlights & Ratios

PEG Ratio0.14

Price to Book (P/B)0.50

Price to Sales (P/S)0.00

P/FCF Ratio-3.57

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-0.15

Revenue Forecast (FY)€462.69K

Bulls Say, Bears Say

Bulls Say

Low Leverage Balance SheetA low debt-to-equity position (~3% TTM) materially reduces near-term solvency risk for a clinical-stage biotech. This structural balance sheet strength gives management more runway and optionality to pursue trials, partnerships or asset sales without heavy interest burdens.

Focused Immune-oncology PipelineConcentrated expertise in cell-based immune-oncology aligns with a durable, growing therapeutic market. A clear scientific focus increases the chance of program synergies, targeted trial design and attractive partnering opportunities, supporting long-term strategic value if trials advance.

Reducing Cash Burn TrendMeasured reduction in cash burn over recent years indicates improving cost control or program prioritization. While still negative, a declining burn rate is a durable operational improvement that lengthens runway and improves the odds of reaching value-inflection events or negotiating better partnership terms.

Bears Say

Revenue CollapsedThe near-total loss of revenue removes any product-derived cushion against R&D cost pressure and makes the company wholly dependent on financing or deals. Long-term growth and margin recovery require successful commercialization or sustained external funding, raising structural risk.

Persistent Negative Cash FlowConsistent negative operating and free cash flow means the business is not self-funding and erodes liquidity over time. Even with improving trends, recurring cash deficits necessitate external capital, constrain strategic choices, and elevate dilution or creditor risk for future development.

Dependence On External FinancingWith no recurring product revenue, the company must rely on equity financings, partnerships or asset sales to fund operations. This structural dependence increases dilution risk, can slow programs if funding gaps occur, and makes long-term execution contingent on capital markets or partners.

1YG0 FAQ

What was Immunicum AB’s price range in the past 12 months?

Immunicum AB lowest stock price was €0.35 and its highest was €0.87 in the past 12 months.

What is Immunicum AB’s market cap?

Immunicum AB’s market cap is €32.47M.

When is Immunicum AB’s upcoming earnings report date?

Immunicum AB’s upcoming earnings report date is Aug 20, 2026 which is in 91 days.

How were Immunicum AB’s earnings last quarter?

Immunicum AB released its earnings results on May 08, 2026. The company reported -€0.031 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.031.

Is Immunicum AB overvalued?

According to Wall Street analysts Immunicum AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Immunicum AB pay dividends?

Immunicum AB does not currently pay dividends.

What is Immunicum AB’s EPS estimate?

Immunicum AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Immunicum AB have?

Immunicum AB has 62,584,580 shares outstanding.

What happened to Immunicum AB’s price movement after its last earnings report?

Immunicum AB reported an EPS of -€0.031 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -7.226%.

Which hedge fund is a major shareholder of Immunicum AB?

Currently, no hedge funds are holding shares in DE:1YG0

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Immunicum AB

Mendus AB (publ), a biopharmaceutical company, develops immunotherapies and relapse vaccines for the treatment of cancer. Its lead product is ilixadencel, which is in Phase II MERECA clinical trial for the treatment of kidney cancer; and Phase I/II clinical trial to treat liver cancer and gastrointestinal stromal tumors. The company's products also comprise DCP-001, which is in Phase II ADVANCE-II clinical trial for the treatment of acute myeloid leukemia; and Phase I/II ALISON clinical trial for the treatment of ovarian cancers. It has a research collaboration with PCI Biotech Holding ASA for novel cancer vaccination treatment; and with Icahn School of Medicine at Mount Sinai. The company was formerly known as Immunicum AB (publ) and changed its name to Mendus AB (publ) in June 2022. Mendus AB (publ) was incorporated in 2002 and is headquartered in Stockholm, Sweden.